Revelation Biosciences, Inc. REVB
Set alert
4.03 USD +0.29 +7.75%
At close · Oct 30
3.92 -0.11 -2.63%
After hours · Oct 30, 4:57 PM ET
3.75 Day range 4.03
3.20 52-week range 26.57
- YTD
- +25.94%
- 1 year
- -19.40%
- Open
- 3.79
- Prev close
- 3.74
- Mkt cap
- 2.29M
- Vol
- 22.21K
- Avg vol
- 10.54K
- EPS
- 32.20
- P/E
- 0.13
- Div yield
- 0.00%
More statistics
- Low
- 3.75
- High
- 4.03
- Forward P/E
- -0.13
- Beta
- 0.00
- Short ratio
- 0.11
- Inst. own
- 8.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 0.7149
- 200-d avg
- 1.49
- 1y target
- 12.75
MAX chart
Events in this range
- Feb 1, 2023Split: 1 for 35
- Jan 25, 2024Split: 1 for 30
- Mar 22, 2024Earnings: -8.33; estimate -10.94; surprise 23.86%
- May 10, 2024Earnings: -2.46; estimate -5.39; surprise 54.36%
- May 10, 2024Earnings: —; estimate -5.39; surprise —%
- Aug 9, 2024Earnings: -1.54; estimate -1.81; surprise 14.92%
- Aug 9, 2024Earnings: —; estimate -1.81; surprise —%
- Nov 8, 2024Earnings: -0.84; estimate -2.84; surprise 70.42%
- Jan 28, 2025Split: 1 for 16
- Jul 7, 2025Split: 1 for 3
- Jan 28, 2026Split: 1 for 4
- Oct 20, 2026Split: 1 for 7
Signals (47)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| SMA: Bullish | Jul 13, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| SMA: Bullish | Dec 29, 2025 | 10 months ago |
| SMA: Bullish | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 5, 2025 | 1 year ago |
| RSI: Oversold | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| SMA: Bullish | Dec 30, 2024 | 1 year ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| SMA: Bullish | Jun 3, 2024 | 2 years ago |
| SMA: Bearish | Dec 4, 2023 | 2 years ago |
| SMA: Bullish | Nov 20, 2023 | 2 years ago |
| SMA: Bearish | Sep 11, 2023 | 3 years ago |
| SMA: Bullish | Sep 4, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| RSI: Oversold | Feb 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| RSI: Oversold | Jul 25, 2022 | 4 years ago |
| SMA: Bearish | Jul 18, 2022 | 4 years ago |
| SMA: Bullish | Jun 27, 2022 | 4 years ago |
| MACD: Buy Signal | May 2, 2022 | 4 years ago |
| SMA: Bearish | Mar 28, 2022 | 4 years ago |
| SMA: Bullish | Mar 21, 2022 | 4 years ago |
| SMA: Bearish | Jan 3, 2022 | 4 years ago |
| SMA: Bearish | Jan 3, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 3, 2022 | 4 years ago |
| RSI: Oversold | Jan 3, 2022 | 4 years ago |
| RSI: Overbought | Nov 29, 2021 | 4 years ago |
| SMA: Bullish | Aug 30, 2021 | 5 years ago |
| SMA: Bullish | Aug 16, 2021 | 5 years ago |
| SMA: Bearish | Jul 12, 2021 | 5 years ago |
| SMA: Bullish | Jul 5, 2021 | 5 years ago |
| SMA: Bearish | Jun 28, 2021 | 5 years ago |
| SMA: Bullish | Jun 7, 2021 | 5 years ago |
| SMA: Bearish | May 3, 2021 | 5 years ago |
| SMA: Bullish | Apr 26, 2021 | 5 years ago |
| SMA: Bearish | Mar 1, 2021 | 5 years ago |
Key statistics
- Market cap
- 2.53M
- Enterprise value
- -5.27M
- Trailing P/E
- 0.00
- Forward P/E
- -0.13
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.49
- EPS (TTM)
- -17.53
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -6.49M
- Total cash
- 6.54M
- Total debt
- 0
- Return on equity
- -270.02%
- Shares outstanding
- 8.36M
- Short % of float
- 2.93%
- 50-day average
- 0.7149
- 200-day average
- 1.49
Analyst view
Consensus: none
Price target (mean) 12.75 +216.4% upside
Now 4.03
- Target (low)
- 5.50
- Target (mean)
- 12.75
- Target (high)
- 20.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -0.43.
Financials — quick view
REVB Revenue — quarterly 0
REVB Net income — quarterly -3.32M
REVB EPS — quarterly -6.10
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -2.84 | -0.84 | +2.00 | +70.42% |
| Aug 9, 2024 | Jun 1, 2024 | -1.81 | -1.54 | +0.27 | +14.92% |
| Aug 9, 2024 | Jun 1, 2024 | -1.81 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -5.39 | -2.46 | +2.93 | +54.36% |
| May 10, 2024 | Mar 1, 2024 | -5.39 | — | — | — |
| Mar 22, 2024 | Dec 1, 2023 | -10.94 | -8.33 | +2.61 | +23.86% |
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- revbiosciences.com
News
- Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
- Revelation Biosciences Announces 1-For-7 Reverse Stock Split, Effective Oct. 20
- Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury
- Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
- Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
- Revelation Biosciences Cites Independent Market Assessment Indicating A $94B Total Addressable Market For Its Gemini Kidney Treatment
- Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
Your note
Sign in to keep a note on REVB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| TIDMARSH GEORGE F | Director | Sale | Dec 7, 2023 | 42,096 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 0.51% | 42,226 | 12.77K | Sep 29, 2024 |
| UBS Group AG | 0.49% | 40,945 | 12.38K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.16% | 13,258 | 4.01K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 2,539 | 767 | Sep 29, 2024 |
| Pom Investment Strategies, LLC | 0.00% | 1 | 0 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 29 | 8 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.10% | 8,022 | 2.42K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 2,942 | 889 | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 201 | 60 | Sep 29, 2024 |